Laboratory of America Holdings (Laboratory of America Holdings) 5-Year Yield-on-Cost %

: 1.46 (As of Today)

View and export this data going back to 1991. Start your Free Trial

Laboratory of America Holdings's yield on cost for the quarter that ended in Dec. 2023 was 1.46.

The historical rank and industry rank for Laboratory of America Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:

LH' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.32 Med: 1.31 Max: 1.56
Current: 1.46

During the past 13 years, Laboratory of America Holdings's highest Yield on Cost was 1.56. The lowest was 0.32. And the median was 1.31.

LH's 5-Year Yield-on-Cost % is ranked worse than
64.86% of 74 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.465 vs LH: 1.46

Competitive Comparison

For the Diagnostics & Research subindustry, Laboratory of America Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laboratory of America Holdings 5-Year Yield-on-Cost % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Laboratory of America Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Laboratory of America Holdings's 5-Year Yield-on-Cost % falls into.

Laboratory of America Holdings 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Laboratory of America Holdings is calculated as

Yield-on-Cost

Dividend Yield %

Dividend Growth Rate)^5

Laboratory of America Holdings (NYSE:LH) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Laboratory of America Holdings 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Laboratory of America Holdings's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.

Laboratory of America Holdings (Laboratory of America Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Laboratory Corp of America Holdings (NYSE:LH) » Definitions » 5-Year Yield-on-Cost %

Comparable Companies

Traded in Other Exchanges

LH:Mexico L1CA34:Brazil

Address

358 South Main Street, Burlington, NC, USA, 27215

Website

https://www.labcorp.com

Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

Executives

Peter J Wilkinson	officer: SVP, Chief Accounting Officer	C/O PHARMACEUTICAL PRODUCT DEVELOPMENT, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Kerrii B Anderson	director	WENDY'S INTERNATIONAL, INC, 4288 WEST DUBLIN-GRANVILLE RD., DUBLIN OH 43017
Van Der Vaart Sandra D	officer: SVP, Global General Counsel	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Paul Rothman	director	6 MEADOW ROAD, BALTIMORE MD 21212
Paul R Kirchgraber	officer: CEO, Covance Drug Development	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Mark S Schroeder	officer: EVP, President-Diagnostics Lab	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Megan D. Bailey	officer: EVP, Chief Strategy Officer	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Jonathan P. Divincenzo	officer: EVP, Pres, Central Labs & Intl	940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Anita Z Graham	officer: EVP, CHRO	C/O THE ADT CORPORATION, 1501 YAMATO ROAD, BOCA RATON FL 33431
Thomas Pike	officer: Pres & CEO Clinical Business	C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601
Kirsten Marie Kliphouse	director	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg	officer: Chief Financial Officer, EVP	P O BOX 1017, CHARLOTTE NC 28201-1017
Brian J Caveney	officer: SVP, Chief Medical Officer	531 SOUTH SPRING STREET, BURLINGTON NC 27215
R Sanders Williams	director	DUKE UNIVERSITY SCHOOL OF MEDICINE, TRENT DRIVE, DURHAM NC 27706
Amy B. Summy	officer: EVP, Chief Marketing Officer	531 SOUTH SPRING STREET, BURLINGTON NC 27215